BACKGROUND: Although polymyositis and dermatomyositis are regarded as treatable disorders, prognosis is not well known, as in the literature long-term outcome and prognostic factors vary widely. AIM: To analyse the prognostic outcome factors in polymyositis and adult dermatomyositis. METHODS: We determined mortality, clinical outcome (muscle strength, disability, persistent use of drugs and quality of life) and disease course and analysed prognostic outcome factors. RESULTS: Disease-related death occurred in at least 10% of the patients, mainly because of associated cancer and pulmonary complications. Re-examination of 110 patients after a median follow-up of 5 years showed that 20% remained in remission and were off drugs, whereas 80% had a polycyclic or chronic continuous course. The cumulative risk of incident connective tissue disorder in patients with myositis was significantly increased. 65% of the patients had normal strength at follow-up, 34% had no or slight disability, and 16% had normal physical sickness impact profile scores. Muscle weakness was associated with higher age (odds ratio (OR) 3.6; 95% confidence interval (CI) 1.3 to 10.3). Disability was associated with male sex (OR 3.1; 95% CI 1.2 to 7.9). 41% of the patients with a favourable clinical outcome were still using drugs. Jo-1 antibodies predicted the persistent use of drugs (OR 4.4, 95% CI 1.3 to 15.0). CONCLUSIONS: Dermatomyositis and polymyositis are serious diseases with a disease-related mortality of at least 10%. In the long term, myositis has a major effect on perceived disability and quality of life, despite the regained muscle strength.
BACKGROUND: Although polymyositis and dermatomyositis are regarded as treatable disorders, prognosis is not well known, as in the literature long-term outcome and prognostic factors vary widely. AIM: To analyse the prognostic outcome factors in polymyositis and adult dermatomyositis. METHODS: We determined mortality, clinical outcome (muscle strength, disability, persistent use of drugs and quality of life) and disease course and analysed prognostic outcome factors. RESULTS: Disease-related death occurred in at least 10% of the patients, mainly because of associated cancer and pulmonary complications. Re-examination of 110 patients after a median follow-up of 5 years showed that 20% remained in remission and were off drugs, whereas 80% had a polycyclic or chronic continuous course. The cumulative risk of incident connective tissue disorder in patients with myositis was significantly increased. 65% of the patients had normal strength at follow-up, 34% had no or slight disability, and 16% had normal physical sickness impact profile scores. Muscle weakness was associated with higher age (odds ratio (OR) 3.6; 95% confidence interval (CI) 1.3 to 10.3). Disability was associated with male sex (OR 3.1; 95% CI 1.2 to 7.9). 41% of the patients with a favourable clinical outcome were still using drugs. Jo-1 antibodies predicted the persistent use of drugs (OR 4.4, 95% CI 1.3 to 15.0). CONCLUSIONS:Dermatomyositis and polymyositis are serious diseases with a disease-related mortality of at least 10%. In the long term, myositis has a major effect on perceived disability and quality of life, despite the regained muscle strength.
Authors: C Vitali; S Bombardieri; H M Moutsopoulos; J Coll; R Gerli; P Y Hatron; L Kater; Y T Konttinen; R Manthorpe; O Meyer; M Mosca; P Ostuni; R A Pellerito; Y Pennec; S R Porter; A Richards; B Sauvezie; M Schiødt; M Sciuto; Y Shoenfeld; F N Skopouli; J S Smolen; F Soromenho; M Tishler; M J Wattiaux Journal: Ann Rheum Dis Date: 1996-02 Impact factor: 19.103
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: N C Notermans; J H Wokke; H Franssen; Y van der Graaf; M Vermeulen; L H van den Berg; P R Bär; F G Jennekens Journal: J Neurol Neurosurg Psychiatry Date: 1993-10 Impact factor: 10.154
Authors: L A Love; R L Leff; D D Fraser; I N Targoff; M Dalakas; P H Plotz; F W Miller Journal: Medicine (Baltimore) Date: 1991-11 Impact factor: 1.889
Authors: Laura C Cleary; Leslie J Crofford; Douglas Long; Richard Charnigo; Jody Clasey; Francesca Beaman; Kirk A Jenkins; Natasha Fraser; Archana Srinivas; Nicole Dhaon; Beatriz Y Hanaoka Journal: Arthritis Care Res (Hoboken) Date: 2015-07 Impact factor: 4.794
Authors: M O Harris-Love; J A Shrader; D Koziol; N Pahlajani; M Jain; M Smith; H L Cintas; C L McGarvey; L James-Newton; A Pokrovnichka; B Moini; I Cabalar; D J Lovell; R Wesley; P H Plotz; F W Miller; J E Hicks; L G Rider Journal: Rheumatology (Oxford) Date: 2008-12-11 Impact factor: 7.580
Authors: Rohit Aggarwal; Andriy Bandos; Ann M Reed; Dana P Ascherman; Richard J Barohn; Brian M Feldman; Frederick W Miller; Lisa G Rider; Michael O Harris-Love; Marc C Levesque; Chester V Oddis Journal: Arthritis Rheumatol Date: 2014-03 Impact factor: 10.995